Clinical trials: Continuous Insulin Infusion System
Type 1 Diabetes
Continuous Subcutaneous Infusion of Pramlintide and Insulin
The purpose of this study is to see if giving the study drug in a slow and steady dose will lower blood sugars during the meal and after-meal time.
- Trial name
- NCT00291772
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Type 1 Diabetes
Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions
The main objective of this study is to determine whether day and night closed-loop insulin delivery for 12 weeks under free living conditions is superior to addition of real-time continuous glucose monitoring in adults with type…
- Trial name
- AP@home04 (NCT01961622)
- Testing
- Florence D2A or similar closed loop glucose control system, CSII with real-time CGM
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 33 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 1
Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump
To investigate the effectiveness and safety of a Real Time Continuous Glucose Monitoring System (RT-CGMS in a population of patients with type 1 diabetes mellitus treated with insulin through an implanted pump.
- Trial name
- IP_RT-CGMS (NCT00501072)
- Testing
- Real-Time Continuous Glucose monitoring System (RT-CGMS)
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Medical Research Foundation, The Netherlands
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external…
- Trial name
- onset® 4 (NCT01999322)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 2 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes, Insulin Therapy
Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update
The aim of this observational clinical trial is to obtain data on the safety, efficacy and satisfaction of the Tandem T:Slim X:2 Pump System in patients with type 1 diabetes.
- Trial name
- UNIQUE (NCT05118945)
- Testing
- Insulin pump Tandem: t:slim X2
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Kinderkrankenhaus auf der Bult
Diabetes Mellitus Type 1
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy.
- Trial name
- Insight Kids (NCT02403375)
- Testing
- Accu-Chek Insight Pump System
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Diabetes Mellitus, Type 1
Closing the Loop 24/7 in Adolescents With Type 1 Diabetes
Type 1 diabetes (T1D) is one of the most common chronic childhood diseases requiring lifelong insulin therapy. Children and adolescents with T1D need regular insulin injections or the continuous insulin delivery using an insulin…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- DAN04 (NCT01873066)
- Testing
- Closed-loop system, real-time CGM
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Cambridge
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to…
- Trial name
- Onset® 5 (NCT02825251)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 472 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Erectile Dysfunction
Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients
Erectile dysfunction (ED) is a common form of organic sexual dysfunction in males with diabetes, with estimated incidence rates between 35 and 75%.
- Trial name
- ECSIITED (NCT01468519)
- Testing
- Insulin
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Jothydev's Diabetes and Research Centre
Type 1 Diabetes With a Subcutaneous Insulin Pump, Adjustment of the Recommended Basal Insulin Flow Rate in the Event of Physical Activity
Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity
Primary aim: To show that in subjects with type 1 diabetes with a subcutaneous continuous insulin infusion, adjustment of the recommended basal insulin flow rate in the event of physical activity allows the subjects to practice…
- Conditions
- Type 1 Diabetes With a Subcutaneous Insulin Pump, Adjustment of the Recommended Basal Insulin Flow Rate in the Event of Physical Activity, Adjustment of the Recommended Prandial Insulin in the Event of Physical Activity
- Trial name
- DIABRASPORT (NCT01277965)
- Testing
- 50%VO2maxTBR50, 50%VO2max TBR80, 75%VO2max TBR80
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Type 2 Diabetes
Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients
The study will assess the total testosterone and sex hormone-binding globulin levels in men with type 2 diabetes before and after continuous subcutaneous insulin infusion and hypoglycemic drugs treatment.
- Trial name
- NCT03982238
- Testing
- Insulin, Metformin, Dapagliflozin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Majianhua
Type 2 Diabetes Mellitus
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes
Short-term intensive insulin therapy(SIIT) is able to reverse β cell dysfunction and induce glycemic remission in patients with newly diagnosed type 2 diabetes.
- Trial name
- NCT03194945
- Testing
- CSII followed by Lina+MET, CSII followed by Lina, CSII followed by MET
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Sun Yat-sen University
Type 1 Diabetes
Psychological Aspects and Insulin Pump Therapy
The Continuous Subcutaneous Insulin Infusion (CSII) might have an impact on psychological distress and some psychological factors might be predictors of metabolic control; however, very few studies conducted so far were…
- Trial name
- NCT02138188
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Universita di Verona
Type 1 Diabetes
Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes
The purpose of the study is to present evidence based literature and clinical data to the medical directors at Missouri Medicaid to help modify the existing policy regarding insulin pump therapy in pediatric patients with…
- Trial name
- NCT00829062
- Testing
- Continuous glucose glucose sensor- physician ordered
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Type 1 Diabetes
CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study
Glycaemic control is an important aspect of Type 1 diabetes (T1D) management for diabetologists and patients alike. Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective method of achieving this.
- Trial name
- NCT02258945
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Liverpool John Moores University
Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Achieving near-normoglycemia has been established as the main objective for most patients with type 1 diabetes (T1DM). However, insulin dosing is an empirical process and its success is highly dependent on the patients' and…
- Trial name
- NCT01550809
- Testing
- iBolus, tBolus (traditional bolus)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Diabetes type1
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
This is a randomized, cross-over study. The aim of this study is to compare the post-prandial glycaemic variability after pure protein meal following with an administration of square-wave bolus of meal-insulin or without any…
- Trial name
- NCT02685449
- Testing
- Insulin glulisine, Insulin aspart, Insulin lispro
- Where
- Poland
- Volunteers
- 70 people
- Sponsor
- Medical University of Warsaw
Type 1 Diabetes Mellitus
The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme.
- Trial name
- NCT03101865
- Testing
- FlorenceM
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- University of Cambridge